Adverum Biotechnologies Announces 3-Year Efficacy and Safety

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction...

Related Keywords

United Kingdom , San Francisco , California , United States , American , Laurent Fischer , Carld Regillo , Carl Regillo , Exchange Commission , Adverum Biotechnologies Inc , Healthcare Products Regulatory Agency , European Medicines Agency , American Academy Of Ophthalmology , Nasdaq , Globenewswire Inc , Drug Administration , Clinical Program Milestones , Retina Service , Retina Subspecialty Day , Extension Data , Gene Therapy , Preliminary Data , Year Results From , Protein Data Highlights , Baseline Characteristics , Clinical Program , Program Milestones , Eye Hospital , Fast Track , Medicines Agency , Innovation Passport , Private Securities Litigation Reform Act , Quarterly Report , Markets ,